ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witek, T.J.
Right arrow Articles by Mahler, D.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witek, T.J., Jr
Right arrow Articles by Mahler, D.A.
Eur Respir J 2003; 21:267-272
Copyright ©ERS Journals Ltd 2003

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

T.J. Witek, Jr1 and D.A. Mahler2

1 Respiratory Development and Operations, Boehringer Ingelheim GmbH, Ingelheim, Germany. 2 Dartmouth­Hitchcock Medical Center, Lebanon, NH, USA

CORRESPONDENCE: T.J. Witek Jr, Boehringer Ingelheim GmbH, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany. Fax: 49 6132776187. E-mail: witek@ing.boehringer­ingelheim.com

Keywords: chronic obstructive pulmonary disease, dyspnoea, symptoms, tiotropium, transition dyspnoea index

Received: July 31, 2002
Accepted August 27, 2002

Supported by Boehringer Ingelheim Pharmaceuticals, Inc. Presented, in part, at the American Thoracic Society Meeting, May 2002.

Dyspnoea is a primary symptom of chronic obstructive pulmonary disease (COPD). The baseline (BDI) and transition (TDI) dyspnoea indices are commonly used instruments to assess breathlessness and the impact of intervention. Its validity and pattern of response in multinational clinical trials has not been established.

In a retrospective analysis of a cohort of 997 COPD patients who received tiotropium, salmeterol or placebo, in addition to usual care, the validity and pattern of response of the BDI and TDI were examined.

The BDI was significantly correlated with the dyspnoea diary (DD) score and the symptom and activity components of the St. George's respiratory questionnaire (SGRQ), establishing concurrent validity. Furthermore, the TDI was also correlated with the changes in DD, SGRQ symptom and activity scores. Construct validity was established by the association between baseline forced expiratory volume in one second (FEV1) and BDI and {Delta}FEV1 with TDI. Physician's global evaluation (PGE) was significantly associated with BDI as well as {Delta}PGE with TDI. Significant correlations have also been observed when the cohorts were classified according to native English and native non­English speaking countries. A change in PGE of 1 category (i.e. 2 units on an 8-point scale) was associated with a mean TDI of ~1 unit (0.9–1.3 mean focal score), lending further support to the clinical significance of this change inherent in the instrument's descriptors. TDI responders (i.e. focal score ≥1 unit) used less supplemental salbutamol, had fewer exacerbations and had significantly improved health status as measured by impacts and total SGRQ scores compared with nonresponders.

In conclusion, the transition dyspnoea index is a valid instrument when used in a multinational clinical trial and the patterns of response confirm a 1-unit change in the transition dyspnoea index focal score as being clinically important.




This article has been cited by other articles:


Home page
ChestHome page
A. Majid, J. Guerrero, S. Gangadharan, D. Feller-Kopman, P. Boiselle, M. DeCamp, S. Ashiku, G. Michaud, F. Herth, and A. Ernst
Tracheobronchoplasty for Severe Tracheobronchomalacia: A Prospective Outcome Analysis
Chest, October 1, 2008; 134(4): 801 - 807.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr., J. Behr, K. K. Brown, R. M. du Bois, L. Lancaster, J. A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 75 - 81.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
N. A. Hanania and J. F. Donohue
Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators
Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. A. Mahler, L. A. Waterman, J. Ward, C. McCusker, R. ZuWallack, and J. C. Baird
Validity and Responsiveness of the Self-Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes
Chest, October 1, 2007; 132(4): 1283 - 1290.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. I.M. Versteegh, J. Braun, P. G. Voigt, D. B. Bosman, J. Stolk, K. F. Rabe, and R. A.E. Dion
Diaphragm plication in adult patients with diaphragm paralysis leads to long-term improvement of pulmonary function and level of dyspnea
Eur. J. Cardiothorac. Surg., September 1, 2007; 32(3): 449 - 456.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Ernst, A. Majid, D. Feller-Kopman, J. Guerrero, P. Boiselle, S. H. Loring, C. O'Donnell, M. DeCamp, F. J. F. Herth, S. Gangadharan, et al.
Airway Stabilization With Silicone Stents for Treating Adult Tracheobronchomalacia: A Prospective Observational Study
Chest, August 1, 2007; 132(2): 609 - 616.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
CORRECTION
Thorax, February 1, 2007; 62(2): 191 - 191.
[Full Text] [PDF]


Home page
NEJMHome page
D. P. Tashkin, R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, D. E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, et al.
Cyclophosphamide versus placebo in scleroderma lung disease.
N. Engl. J. Med., June 22, 2006; 354(25): 2655 - 2666.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
O. Diaz, P. Begin, M. Andresen, M. E. Prieto, C. Castillo, J. Jorquera, and C. Lisboa
Physiological and clinical effects of diurnal noninvasive ventilation in hypercapnic COPD
Eur. Respir. J., December 1, 2005; 26(6): 1016 - 1023.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
B. Barrett, D. Brown, M. Mundt, and R. Brown
Sufficiently Important Difference: Expanding the Framework of Clinical Significance
Med Decis Making, May 1, 2005; 25(3): 250 - 261.
[Abstract] [PDF]


Home page
ChestHome page
R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek Jr, and S. Kesten
Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD
Chest, March 1, 2005; 127(3): 809 - 817.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell
Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study
Chest, September 1, 2004; 126(3): 926 - 934.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Eur. Respir. J., June 1, 2004; 23(6): 832 - 840.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the European Respiratory Society.